Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 8% Improvement Relative Risk Blanch-Rubió et al. Vitamin D for COVID-19 Prophylaxis Does vitamin D reduce COVID-19 infections? Retrospective 2,102 patients in Spain No significant difference in cases Blanch-Rubió et al., Aging, doi:10.18632/aging.104117 Favors vitamin D Favors control
Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions
Blanch-Rubió et al., Aging, doi:10.18632/aging.104117
Blanch-Rubió et al., Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory.., Aging, doi:10.18632/aging.104117
Oct 2020   Source   PDF  
  All Studies   Meta
Retrospective 2,102 rheumatology patients in Spain showing no significant difference in cases with vitamin D supplementation. Details of vitamin D supplementation are not providied - other patients may have also independently taken vitamin D.
risk of case, 8.0% lower, RR 0.92, p = 0.68, treatment 62 of 1,303 (4.8%), control 47 of 799 (5.9%), adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Blanch-Rubió et al., 20 Oct 2020, retrospective, Spain, peer-reviewed, mean age 66.4, 10 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: AGING 2020, Vol. 12, No. 20 Research Paper Influence of anti-osteoporosis treatments on the incidence of COVID19 in patients with non-inflammatory rheumatic conditions Josep Blanch-Rubió1,2,*, Natalia Soldevila-Domenech3,7,*, Laura Tío2, Jone Llorente-Onaindia2, Manuel Ciria-Recasens1,2, Luciano Polino2, Alba Gurt5, Rafael de la Torre3,6,7, Rafael Maldonado2,4,§, Jordi Monfort1,2,§, and the Covidmar Study Group# 1 Rheumatology Service, Hospital del Mar, Passeig Marítim, Barcelona 08003, Spain IMIM (Hospital del Mar Medical Research Institute), PRBB, Barcelona 08003, Spain 3 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIMInstitut Hospital del Mar d’Investigacions Mèdiques, PRBB, Barcelona 08003, Spain 4 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, Barcelona 08003, Spain 5 CAP Vila Olímpica, Parc Sanitari Pere Virgili, Barcelona 08003, Spain 6 Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain 7 Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, Barcelona 08003, Spain *Equal contribution § Equally supervised this work # A list of authors and their affiliations appears in Acknowledgments 2 Correspondence to: Rafael Maldonado; email: Keywords: denosumab, zoledronate, calcium, vitamin D, anti-resorptive drugs, COVID-19 Received: July 21, 2020 Accepted: September 9, 2020 Published: October 20, 2020 Copyright: © 2020 Blanch-Rubió et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Coronavirus disease 19 (COVID-19) is currently a global pandemic that affects patients with other pathologies. Here, we investigated the influence of treatments for osteoporosis and other non-inflammatory rheumatic conditions, such as osteoarthritis and fibromyalgia, on COVID-19 incidence. To this end, we conducted a crosssectional study of 2,102 patients being treated at the Rheumatology Service of Hospital del Mar (Barcelona, Spain). In our cohort, COVID-19 cumulative incidence from March 1 to May 3, 2020 was compared to population estimates for the same city. We used Poisson regression models to determine the adjusted relative risk ratios for COVID-19 associated with different treatments and comorbidities. Denosumab, zoledronate and calcium were negatively associated with COVID-19 incidence. Some analgesics, particularly pregabalin and most of the studied antidepressants, were positively associated with COVID-19 incidence, whereas duloxetine presented a negative association. Oral bisphosphonates, vitamin D, thiazide diuretics, anti-hypertensive drugs and chronic nonsteroidal anti-inflammatory drugs had no effect on COVID-19 incidence in the studied population. Our results provide novel evidence to support the maintenance of the main anti-osteoporosis treatments in COVID-19 patients, which may be of particular relevance to elderly patients affected by the SARS-CoV-2 pandemic.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop